See healthcare not as it is but as it should be. Viatris act courageously and is uniquely positioned to be a source of stability in a world of evolving healthcare needs.

Viatris empower people worldwide to live healthier at every stage of life via:


Providing high quality

trusted medicines

regardless of geography

or circumstance.

Advancing sustainable

operations and innovative solutions to improve patient health.

Leveraging our collective

expertise to connect people

to products and services.

Viatris global portfolio comprises more than 1,400 molecules across a broad range of major therapeutic areas, including best-in-class, iconic brand-name products, as well as global key brands, generics, including branded and complex generics, biosimilars and over-the-counter offerings.

From cardiovascular health to oncology, Viatris offers quality treatment options across more than 10 major therapeutic areas covering a wide variety of noncommunicable and infectious diseases. Viatris also offers beyond the medicine solutions and services such as diagnostics, health literacy support and digital tools to help patients better manage their health. Viatris considers it our duty to advocate for policies that advance knowledge and education, reduce barriers to treatment access to achieve better health for patients and unlock value for health systems.

Founded over 40 years ago, Hikma has been dedicated to providing high-quality, affordable
medicines. Originating in Jordan in 1978, we became a leading supplier of branded generics and
in-licensed products.
Expanding our presence across the Middle East and North Africa (MENA), we established the
first FDA-inspected manufacturing plant in the region. A pivotal moment came with our entry
into Portugal, marking our foray into sterile manufacturing for injectable pharmaceuticals.
Furthering our global reach, we successfully entered the US market by acquiring West-Ward
Pharmaceuticals. Important acquisitions in Tunisia and Saudi Arabia strengthened our position
as a leading provider of generics internationally.
Our commitment to quality is underscored by FDA approvals for manufacturing plants in Saudi
Arabia and Portugal. Diversification into the lyophilized segment in Italy and entry into the
oncology market in Germany showcased our strategic expansion.
The 2005 London Stock Exchange listing facilitated our growth, enabling both organic and
acquisition-driven expansions in the MENA region, Europe, and the United States.
In the last decade, we continued our growth trajectory, acquiring strategic assets in Algeria, the
US, Morocco, and Egypt. Transformative acquisitions like Roxane Laboratories in the US and
FDA approval for a new high containment facility in 2020 further exemplified our commitment to
innovation and quality.
Expanding our presence into Canada. and strengthening our US injectables business.
underscored our commitment to enhancing our product portfolio, pipeline, and research and
development capabilities.



© 2024, 4th Abu Dhabi Integrated Mental Health Conference